Confounding Factors in Targeted Degradation of Short-Lived Proteins

Targeted protein degradation has recently emerged as a novel option in drug discovery. Natural protein half-life is expected to affect the efficacy of degrading agents, but to what extent it influences target protein degradation has not been systematically explored. Using simple mathematical modelin...

Full description

Saved in:
Bibliographic Details
Published in:ACS chemical biology 2024-07, Vol.19 (7), p.1484-1494
Main Authors: Vetma, Vesna, Perez, Laura Casares, Eliaš, Ján, Stingu, Andrea, Kombara, Anju, Gmaschitz, Teresa, Braun, Nina, Ciftci, Tuncay, Dahmann, Georg, Diers, Emelyne, Gerstberger, Thomas, Greb, Peter, Kidd, Giorgia, Kofink, Christiane, Puoti, Ilaria, Spiteri, Valentina, Trainor, Nicole, Weinstabl, Harald, Westermaier, Yvonne, Whitworth, Claire, Ciulli, Alessio, Farnaby, William, McAulay, Kirsten, Frost, Aileen B., Chessum, Nicola, Koegl, Manfred
Format: Article
Language:English
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Targeted protein degradation has recently emerged as a novel option in drug discovery. Natural protein half-life is expected to affect the efficacy of degrading agents, but to what extent it influences target protein degradation has not been systematically explored. Using simple mathematical modeling of protein degradation, we find that the natural half-life of a target protein has a dramatic effect on the level of protein degradation induced by a degrader agent which can pose significant hurdles to screening efforts. Moreover, we show that upon screening for degraders of short-lived proteins, agents that stall protein synthesis, such as GSPT1 degraders and generally cytotoxic compounds, deceptively appear as protein-degrading agents. This is exemplified by the disappearance of short-lived proteins such as MCL1 and MDM2 upon GSPT1 degradation and upon treatment with cytotoxic agents such as doxorubicin. These findings have implications for target selection as well as for the type of control experiments required to conclude that a novel agent works as a bona fide targeted protein degrader.
ISSN:1554-8929
1554-8937
1554-8937
DOI:10.1021/acschembio.4c00152